Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (275)	3/8/1999 9:20:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 810

Very interesting appointment. I met Dr. Hardman at the breakout for MBIO at this year's H&Q. He quickly understood the question that I was asking and gave me a pointer for follow-up. He doesn't seem like the COO type to me, having run the show at Gene Medicine. He's a bit well-dressed for my taste, but I liked him. ;-) This is the second interesting new-hire, IMO, that Renton has made. He also hired an ex-boss of mine, a guy with competence up his wazoo. This organization has professional polish, from what I have seen. Monday March 8, 4:35 pm Eastern Time Company Press Release SOURCE: Onyx Pharmaceuticals Inc. Norman Hardman to Join Onyx as Chief Operating Officer RICHMOND, Calif., March 8 /PRNewswire/ -- Onyx Pharmaceuticals Inc., (Nasdaq: ONXX - news) announced today that Norman Hardman, Ph.D., will join the company as chief operating officer. He is currently serving as president and chief operating officer of GENEMEDICINE INC., located in The Woodlands, Texas, and intends to join Onyx following completion of the pending merger between GENEMEDICINE INC. and Megabios Corporation, Burlingame, California. This merger is expected to be completed before the end of the month. In his new post at Onyx, Dr. Hardman will focus on managing the company's research and development efforts across both the therapeutic virus and small molecule platforms. He will oversee discovery research and development, preclinical and clinical research and development, project management, regulatory affairs, and manufacturing sciences. ''Norman has extensive experience in drug discovery and development, both in the biotech and in the large pharmaceutical setting,'' said Hollings Renton, chief executive officer of Onyx. ''His expertise will be of key importance to us as we move our lead anticancer drug, ONYX-015, into Phase III clinical trials later this year. In addition, we are on a critical path in the development of lead candidates in both our virus and small molecule platforms. Norman's contributions will be invaluable as we pursue aggressive preclinical and clinical development of these new products.'' Dr. Hardman has held positions of increasing responsibility in the biotechnology and pharmaceutical industries over the past 12 years. He joined GENEMEDICINE INC. in 1997, serving initially as senior vice president of research and preclinical development and chief scientific officer, and later as chief operating officer. Dr. Hardman was named president of GENEMEDICINE INC. in 1998. From 1996 to 1997, Dr. Hardman headed research and preclinical development operations for Novartis Pharmaceuticals UK and was a member of the global R&D boards. He served as head of pharma research in the UK for Ciba Pharmaceuticals Ltd., a division of Ciba-Geigy AG, between 1993 and 1996. Prior to that he spent five years in the biotechnology section of Ciba-Geigy, Basel, initially as project leader and subsequently as head of molecular biology. Dr. Hardman holds a doctorate degree in biochemistry from the University of Manchester, UK, and a bachelor of science degree in chemistry from the University of London. He is listed as an inventor on seven international patents and has authored more than 70 articles in the scientific literature. Onyx Pharmaceuticals was founded in 1992 for the purpose of discovering and developing novel therapeutics based upon the genetics of human disease, with an emphasis on cancer. The company focuses on defining the function of certain mutated genes which are known to cause cancer, and on developing innovative therapies to reverse the effects of the mutation or to kill the cancer cell. Onyx pursues a strategy of establishing corporate partnerships that provide complementary skills in chemistry, drug development, and marketing and sales. This press release contains certain forward-looking statements with regard to the development of potential human therapeutic products that involve a number of risks and uncertainties. Actual events may differ from the company's expectations. In addition to the matters described in this press release, the timeline for clinical activity, results of pending or future clinical trials, including the trials of ONYX-015, and changes in the status of the company's collaborative relationships, as well as the risk factors listed from time to time in the company's periodic reports filed with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10-K, may affect the actual results achieved by the company. SOURCE: Onyx Pharmaceuticals Inc.